Bausch & Lomb
One Bausch & Lomb Place
318 articles with Bausch & Lomb
Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2022 financial results on Wednesday, June 8, 2022.
Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, has filed its financial statements for the quarter ended March 31, 2022, in accordance with applicable Canadian securities laws.
Bausch + Lomb Corporation announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m. ET.
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Bausch + Lomb Corporation released findings from a survey designed to gain an understanding of retina specialists' need for a new treatment option for patients with macular edema associated with noninfectious uveitis and the new drug delivery method in which treatment is administered via the suprachoroidal space.
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
Bausch + Lomb Corporation launched as a publicly traded company focused on protecting and enhancing the gift of sight for millions of people around the world when it began trading under the "BLCO" symbol on the New York Stock Exchange and Toronto Stock Exchange.
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
Bausch + Lomb today announced that data from the second pivotal Phase 3 trial (MOJAVE) of investigational treatment NOV03.
A roundup of last week's top clinical trial updates and news.
Bausch + Lomb Corporation, a wholly owned subsidiary of Bausch Health Companies Inc., announced the launch of its initial public offering and the commencement of the roadshow for the IPO.
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
Bausch + Lomb announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 48,235,850 million units, or 290,145 pounds, of used contact lenses, eye care and lens care materials, which is the equivalent of the weight of approximately 31 elephants.1 Both programs are made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
Bausch Health Companies Inc. announced that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation, is seeking to enter into a new credit agreement, which is expected to include a $2.5 billion term B loan facility and $500 million revolving facility.
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery annual meeting, which will take place from April 22-26, 2022 in Washington, D.C.
Nicox SA, an international ophthalmology company, provides an update on the approvals and launches of VYZULTA, 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc.
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
Bausch Health Companies Inc. announced that it is seeking to refinance its existing credit agreement.
New Survey From Bausch + Lomb And Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients
Bausch + Lomb and Glaucoma Research Foundation, released, during Glaucoma Awareness Month, new key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma.
Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials.
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
Bausch + Lomb announced that seven scientific posters involving the company's products, as well as data from the company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms surveillance study, will be presented during the annual meetings of the American Academy of Optometry in Boston and American Academy of Ophthalmology in New Orleans.
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the launch of the Biotrue® Eye Care Recycling program, the first and only eye care recycling program in the United States.
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid
Xipere was approved for suprachoroidal use for the macular edema treatment. Macular edema is associated with uveitis, it is a form of eye inflammation.